Showing 7931-7940 of 8178 results for "".
- Neodyne Biosciences Announces Positive Interim Trial Results for Embracehttps://practicaldermatology.com/news/20120807-neodyne_biosciences_announces_positive_interim_trial_results_for_embrace/2459756/Neodyne Biosciences, Inc. announced positive interim results from the REFINE Trial (Scar Prevention and the Clinical Effectiveness of a Novel Mechano-modulating Polymer), a randomized, control clinical trial designed to assess the efficacy and
- Abbott 2Q Profit Beats Expectations, Humira Sales Growhttps://practicaldermatology.com/news/20120802-abbott_2q_profit_beats_expectations_humira_sales_grow/2459757/Abbott Laboratories announced that second-quarter earnings narrowly beat estimates, fueled by the continued growth of its drug Humira. The company said net income for the quarter declined to $1.75 billion, or $1.08 per share, from $1.94 b
- National Rosacea Society to Host 20th Anniversary Galahttps://practicaldermatology.com/news/20120730-national_rosacea_society_to_host_20th_anniversary_gala/2459759/The National Rosacea Society is hosting a 20th Anniversary Gala Celebration and Dinner on August 17, 2012, from 6-9pm at the Boston Sheraton Hotel during the summer AAD meeting to give thanks to the countless healthcare professionals who have helped improve the quality of life for rosacea patients w
- Sandoz Completes Acquisition of Fougera Pharmaceuticalshttps://practicaldermatology.com/news/20120727-sandoz_completes_acquisition_of_fougera_pharmaceuticals/2459760/Sandoz has completed its USD $1.525 billion acquisition of specialty dermatology company Fougera Pharmaceuticals. Combined with Sandoz's existing generic dermatology franchise, this acquisition positions Sandoz as the new #1 in generic dermatology
- Veil Cosmetics Introduced to Markethttps://practicaldermatology.com/news/20120727-veil_cosmetics_introduced_to_market/2459761/The concept of makeup artist Sébastien Tardif, Veil Cosmetics was inspired by Tardif's foundation in both art and fashion, which inspired the palette of bright-based colors that lift and illuminate the skin. Tardif cultivated his skincare sensibilities during his tenure in Asia, which led him
- Cone Health Pioneers Use of Fabric That Healshttps://practicaldermatology.com/news/20120726-cone_health_pioneers_use_of_fabric_that_heals/2459762/Studies find that hospital linens and gowns can be transformed into therapeutic tools when made with a smooth, antimicrobial fabric called DermaTherapy. Researchers found that patients using DermaTherapy developed 81.5 percent fewer be
- Alcohol May Influence Skin Cancer Riskhttps://practicaldermatology.com/news/20120720-alcohol_may_influence_skin_cancer_risk/2459766/Evidence suggests that alcohol consumption may have some influence on risk for developing BCC but not SCC. (J Invest Dermatol. E-pub) Consumption of wine and spirits, specifically, appears to increase BCC risk, while beer consumption does not. Results come from an analysis of data on 54,766 people e
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- TriPollar RF Technology Launches for Acne Vulgarishttps://practicaldermatology.com/news/20120712-tripollar_rf_technology_launches_for_acne_vulgaris/2459773/The new Apollo powered by TriPollar utilizes advanced radiofrequency technology—the latest alternative for treating acne, according to the company. A recent study demonstrated that TriPollar technology is
- Syneron Receives FDA Clearance for elōs Plushttps://practicaldermatology.com/news/20120712-syneron_receives_fda_clearance_for_els_plus/2459774/Syneron Medical Ltd. (NASDAQ: ELOS) received US Food and Drug Administration (FDA) clearance for elōs Plus, a multi-platform system featuring the company's proprietary elōs technology of optical energy and bi-polar radiofrequency. The FDA clearance follo